RCUS - ARCUS BIOSCIENCS ()

RCUSのニュース

   Arcus Biosciences to Participate in Upcoming September 2020 Investor Conferences  2020/08/27 20:10:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences: Citi 15th Annual BioPharma Virtual Conference, Wednesday, September 9 at 1:30 pm ET 2020 Cantor Global Virtual Healthcare Conference, Wednesday, September 16 at 4:40pm ET Morgan Stanley Virtual 18th Annual Global Healthcare Confere
   Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates  2020/08/06 20:10:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the second quarter ended June 30, 2020 and provided corporate updates. “The multitude and quality of accomplishments from the Arcus team over the course of these dynamic few months have illustrated Arcus’s extraordinary commitment to its vision to consistently create, develop and deliver life-
   Arcus Biosciences to Participate in Upcoming August Investor Conferences  2020/07/28 20:10:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences: BTIG Virtual Biotechnology Conference 2020, Monday, August 10 at 11:00 am ET 2020 Wedbush PacGrow Healthcare Virtual Conference, Tuesday, August 11 at 1:45 pm ET A live audio webcast of each presentation will be available by visiti
   Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies  2020/07/13 20:05:00 Business Wire
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today the closing of their option and co-development and co-commercialization partnership agreement signed on May 27, 2020. The closing occurred following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
   Bob Goeltz to Join Arcus Biosciences as Chief Financial Officer  2020/07/07 20:10:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz will join Arcus as Chief Financial Officer on August 1, 2020. Mr. Goeltz is a proven financial leader with substantial operational experience in both large and small cap biopharmaceutical company environments. “Following the recent announcement of our 10-year collaboration with Gilead and successful
   Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates  2020/08/06 20:10:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the second quarter ended June 30, 2020 and provided corporate updates. “The multitude and quality of accomplishments from the Arcus team over the course of these dynamic few months have illustrated Arcus’s extraordinary commitment to its vision to consistently create, develop and deliver life-
   Arcus Biosciences to Participate in Upcoming August Investor Conferences  2020/07/28 20:10:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences: BTIG Virtual Biotechnology Conference 2020, Monday, August 10 at 11:00 am ET 2020 Wedbush PacGrow Healthcare Virtual Conference, Tuesday, August 11 at 1:45 pm ET A live audio webcast of each presentation will be available by visiti
   Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies  2020/07/13 20:05:00 Business Wire
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today the closing of their option and co-development and co-commercialization partnership agreement signed on May 27, 2020. The closing occurred following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
   Bob Goeltz to Join Arcus Biosciences as Chief Financial Officer  2020/07/07 20:10:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz will join Arcus as Chief Financial Officer on August 1, 2020. Mr. Goeltz is a proven financial leader with substantial operational experience in both large and small cap biopharmaceutical company environments. “Following the recent announcement of our 10-year collaboration with Gilead and successful
   Arcus Biosciences Announces New Employment Inducement Grants  2020/06/09 20:10:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 138,000 shares of the Company’s common stock at an exercise price per share of $28.96, which was the closing price on June 8, 2020. The stock options were granted pursuant to the Company’s 20

calendar